Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.
What happened
FDA inspected the company's drug manufacturing facility in Chandler, AZ, from January 14 to 23, 2026, and found that OTC drug products were released without process validation (studies proving a process reliably makes the same quality product every time), that equipment cleaning had no validated method to detect drug residues, and that the water system was changed without re-qualification and had repeated results above USP (United States Pharmacopeia) limits that were never investigated. A separate review of product labels found that three acne products carried claims beyond what the OTC acne monograph (FDA's rulebook for marketing these drugs without an approved application) allows, making them unapproved new drugs. FDA also said similar CGMP violations were cited at this facility in 2016 and 2020.
What FDA found
The company released OTC drug batches without process validation, including one product run at a scale beyond its qualified limit.
21 CFR 211.100(a)Cleaning of shared manufacturing equipment was not validated, with no residue-specific test method and no justification for which products were chosen for study.
21 CFR 211.100(a)The water system was modified without adequate re-qualification, and out-of-specification results from its sampling points were not investigated or fixed.
21 CFR 211.100(a)Viscosity failures seen in stability testing of distributed products were not thoroughly investigated, with no root cause, corrective action, or justification for the specifications.
21 CFR 211.192TreeActiv and Ayadara acne products make claims such as 'cystic' and 'severe' acne that go beyond the permitted OTC monograph indications, making them unapproved new drugs.
Section 505(a), FD&C Act, 21 U.S.C. 355(a)TreeActiv and Ayadara are misbranded because they are nonprescription drugs that do not meet the requirements for marketing without an approved application.
Section 502(ee), FD&C Act, 21 U.S.C. 352(ee)
What FDA wants
FDA asks the company to reply in writing within 15 working days describing what it has done to fix the violations and prevent repeat problems, and to supply detailed validation plans, water-system remediation and monitoring plans, risk assessments of products already distributed, and a retrospective review of out-of-specification results. FDA also recommends engaging a qualified CGMP consultant.
Who should pay attention
- brands that buy finished OTC drug products from this contract manufacturer
- distributors and retailers selling TreeActiv, Ayadara or Skin Script acne products
- contract manufacturers of topical OTC drugs relying on external labs for out-of-specification testing
This is a summary. Read the original letter on fda.gov.